In every field of medical science, there are a handful of leaders recognized by their peers as giants. Dr. John Voorhees, MD, FRCP (London), is one such leader. In an illustrious career spanning several decades, Dr. Voorhees has advanced medical knowledge through dermatologic research, developed innovative approaches to psoriasis treatment, taught and mentored dozens of…
Can educational videos reduce disparities in the research and treatment of psoriasis?
In the 38 years he has mentored residents, lectured on dermatology, and run a clinical practice, Dr. Goldfarb has advocated the value of human connection with patients and residents. He believes it inspires trust, enables learning, creates a reciprocal environment of care, and is the central element to bring to a lecture hall, a clinical research unit, or a patient clinic.
Pustular psoriasis is a group of inflammatory skin diseases characterized by visible, sterile pustules on inflamed skin. It appears in generalized and localized forms and can occur in patients with or without a history of psoriasis. Pustular psoriasis has distinct genetic risk factors, inflammatory profile, and response to treatment compared to psoriasis. Thus, it may be its own unique disease. PPP is characterized by sterile pustules on the palms and soles. There is no consensus on optimal treatment , although acitretin, methotrexate, and phototherapy are among the more common treatments.
In March 2022, Dr. Callender received the Dermatology Foundation’s Clark W. Finnerud Award presented to an individual who “most skillfully blends clinical practice with writing and teaching dermatology, thereby serving as a mentor and role model.”
The Distinguished Service Medallion is the highest honor the Foundation confers on a colleague in recognition of exemplary leadership and service to the specialty of dermatology.
New Orleans is renowned for its music, food, and joie de vivre. And now it can add the Dermatology Foundation’s Annual Meeting of Membership to its roster of attractions. The Big Easy was host to an event where people reconnect, acknowledge the year’s successes, and celebrate the people who have received Foundation support.
Dr. Bhutani presented new topical therapies for psoriasis and atopic dermatitis, including tapinarof, roflumilast, and ruxolitinib.
Three extraordinary mid-career investigators with established trajectories of excellence in basic, translational and clinical research will receive DF funding through its DF Research Award Program, now enhanced with the BMS million-dollar donation.
The Sun Pharma Research Award provides Dr. Tiffany Scharschmidt with the focus and freedom to address clinically translational aspects of her research in pediatric atopic dermatitis.